GSK (LON:GSK) Given Hold Rating at Berenberg Bank

Berenberg Bank reissued their hold rating on shares of GSK (LON:GSK) in a research note released on Thursday, MarketBeat Ratings reports. The brokerage currently has a GBX 2,000 price target on the stock.

A number of other research firms have also weighed in on GSK. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Finally, Citigroup boosted their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a report on Monday, February 9th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of GBX 1,966.43.

GSK Price Performance

Shares of LON:GSK opened at GBX 2,046 on Thursday. The company has a market capitalization of £82.07 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.32. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a fifty day moving average of GBX 2,035.68 and a 200-day moving average of GBX 1,827.29. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 2,282.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Anne Beal bought 196 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were bought at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Luke Miels sold 15,579 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Insiders have purchased 11,447 shares of company stock worth $24,273,097 over the last quarter. Company insiders own 0.26% of the company’s stock.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK continued its share repurchase programme, buying 345,000 ordinary shares and lifting treasury holdings to 6.27% of voting rights — reduces float and supports EPS and per‑share metrics. Buyback Update
• Positive Sentiment: GSK Pakistan reported a 53% jump in profit to Rs. 10 billion for 2025 — strong regional operating performance that can add to group profitability and investor confidence in emerging‑market franchise momentum. GSK Pakistan Profit GSK Pakistan Profit (alt)
• Positive Sentiment: GSK struck an alliance with Shanghai Pharma to reintroduce its hepatitis B vaccine in China — expands access to a large market and supports vaccine growth prospects. China Hep B Alliance
• Positive Sentiment: Insider buying reported (Jonathan Symonds 5,000 shares; Wendy Becker 411 shares) — small but constructive insider signal that can reassure investors. Insider Buys – Symonds Insider Buys – Becker
• Positive Sentiment: Shore Capital reaffirmed a “buy” rating — an additional buy‑side endorsement that may attract demand. Shore Capital Buy
• Neutral Sentiment: GSK presented at the Goldman Sachs Biopharma Innovation Summit (transcript available) — useful for investor visibility on pipeline and strategy but unlikely to move the stock unless new data or guidance were announced. Goldman Sachs Presentation
• Negative Sentiment: Berenberg reiterated a “hold” with a GBX 2,000 price target — below the recent trading level and signals limited near‑term upside from that broker, which can act as a headwind to further gains. Berenberg Hold/Price Target

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.